Abstract Number: 1593 • ACR Convergence 2025
Comparison of rituximab induction and maintenance regimens in ANCA-associated vasculitis: PK/PD modelling approach in real-world patients
Background/Purpose: For the treatment of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), rituximab (RTX) may be given as a 4-dose regimen (375 mg/m2 weekly for 4…Abstract Number: 0946 • ACR Convergence 2025
A Novel Preclinical Tool for Evaluating CD20 Antibody Efficacy Based on BAFF/CD20 Dual-target Humanized Mice
Background/Purpose: CD20, a well characterized B-cell surface marker involved in B-cell activation and differentiation, plays a critical role in the pathogenesis of B-cell mediated diseases…Abstract Number: 0843 • ACR Convergence 2025
Efficacy and Safety of BMS-986353, a CD19-Directed Chimeric Antigen Receptor T Cell Therapy Manufactured Using a Next-Generation Process: Updated Data From a Phase 1 Trial in Patients With Systemic Sclerosis
Background/Purpose: BMS-986353 (CC-97540) is an investigational CD19-directed T-cell therapy expressing the chimeric antigen receptor (CAR) used in globally-approved lisocabtagene maraleucel; it is manufactured via the…Abstract Number: 0009 • ACR Convergence 2025
MRT-6160, a VAV1-Directed Molecular Glue Degrader, Attenuates T and B Cell Effector Functions and Inhibits Disease Progression in a Spontaneous MRL-Faslpr Mouse Model
Background/Purpose: VAV1, an immune cell restricted guanine nucleotide exchange factor (GEF) and scaffolding protein, plays a critical role in mediating T- and B-cell receptor activity.…Abstract Number: 2463 • ACR Convergence 2025
Allogenic anti- CD19 CAR-T cells induce remission in refractory systemic lupus erythematosus
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease associated with significant morbidity and mortality. The treatment approach for SLE primarily involves immunomodulation and…Abstract Number: 1578 • ACR Convergence 2025
Use of the CD19/CD3 T cell engager blinatumomab in refractory diffuse systemic sclerosis : a case series
Background/Purpose: Systemic sclerosis (SSc) is a severe autoimmune disease with limited treatments. While anti-CD19 CAR T-cell therapy shows promise, its use is limited by cost…Abstract Number: 0943 • ACR Convergence 2025
Type I and Type II IFNs have both independent and overlapping effects on SLE disease severity
Background/Purpose: The pathogenesis of systemic lupus erythematosus (SLE) is thought to be strongly influenced by the interferon (IFN) signaling pathway, particularly type I IFNs (IFNα/β).…Abstract Number: 0804 • ACR Convergence 2025
Comparative Risk of All-Cause Mortality with Belimumab versus Oral Immunosuppressant Use in Patients with Non-Renal Systemic Lupus Erythematosus
Background/Purpose: Belimumab is a monoclonal antibody targeting B-lymphocyte stimulator (BLyS) used in the treatment of active systemic lupus erythematosus (SLE). Our objective was to investigate…Abstract Number: 0008 • ACR Convergence 2025
Characterization of S-1117, a novel pan-IgG protease engineered for reduced immunogenicity using the IMPACT platform
Background/Purpose: Pathogenic autoantibodies are key effectors of inflammation, promoting tissue damage in autoantibody-mediated diseases such as inflammatory myopathies, lupus nephritis, Sjogren’s syndrome, antiphospholipid syndrome, and…Abstract Number: 2458 • ACR Convergence 2025
Obecabtagene autoleucel (obe-cel), a CD19-targeting Autologous Chimeric Antigen Receptor T-cell Therapy (CAR T) with a fast off-rate binding domain, in Patients (pts) with Severe, Refractory Systemic Lupus Erythematosus (srSLE): Preliminary Results from the Phase I CARLYSLE Study
Background/Purpose: Pts with srSLE have limited remaining treatment options and represent a population with an unmet need. CD19 CAR Ts have potential for deep depletion…Abstract Number: 1563 • ACR Convergence 2025
RESET-SSc: Clinical Trial Evaluating Rese-cel (Resecabtagene Autoleucel), A Fully Human, Autologous 4-1BB CD19-CAR T Cell Therapy in Systemic Sclerosis
Background/Purpose: The treatment goals for systemic sclerosis (SSc) are to control disease activity, limit progression of organ damage and decrease long-term morbidity and mortality. Therapies…Abstract Number: 0914 • ACR Convergence 2025
Preclinical Expansion of Autoreactive Naive B cells Drives RA onset in ACPA+ individuals
Background/Purpose: The cellular and molecular mechanisms underlying the progression from anti-citrullinated protein antibody (ACPA) positivity to clinical rheumatoid arthritis (RA) remain poorly understood. Defining these…Abstract Number: 0279 • ACR Convergence 2025
Assessment of Baseline IgG4-RD Disease Characteristics and Impact Upon Safety and Efficacy of Inebilizumab: Results from the MITIGATE Study
Background/Purpose: IgG4-related disease (IgG4-RD) is a progressive, systemic, fibroinflammatory disease characterized by unpredictable and recurring flares, leading to organ damage and decreased quality of life.…Abstract Number: 0006 • ACR Convergence 2025
QEL-005: CD19 CAR-Regulatory T cell therapy, a novel approach for the treatment of complex immune mediated inflammatory diseases including Rheumatoid Arthritis and Systemic Sclerosis
Background/Purpose: Rheumatoid Arthritis (RA) and Systemic Sclerosis (SSc) are immune mediated inflammatory diseases (IMID) where a complex interplay of tissue and immune cell activation drives…Abstract Number: 2448 • ACR Convergence 2025
Rituximab as the first line treatment in newly diagnosed systemic lupus erythematosus
Background/Purpose: Rituximab (RTX) has been commonly used for the treatment of patients with severe or refractory systemic lupus erythematosus (SLE), yet real-world data concerning RTX…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 17
- Next Page »
